Navigation Links
Avrio Receives Drug Manufacturing License and Medical Device Manufacturing License from the California Food and Drug Branch
Date:2/10/2010

IRVINE, Calif., Feb. 10 /PRNewswire/ -- Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.  

Avrio's newly built, 20,000 square foot, state-of-the-art, aseptic fill-and-finish facility includes three aseptic suites and five production suites with each suite having its own dedicated air handling system. With great confidence in the newly built infrastructure, strategic manufacturing-process flow, state-of-the-art equipment, and experienced staff, Avrio boasts its level of quality by offering clients live video viewing of production (along with on-site viewing access). In addition to a production area designed to provide clients flexibility and scalability, Avrio also includes laboratory space for quality control, microbiology, formulation, and a pilot suite. Furthermore, Avrio's affiliate, Irvine Pharmaceutical Services, Inc., located just across the street, has over 65,000 square feet of laboratory space which provides complete cGMP analytical CMC support.

With multiple manufacturing contracts in place and a number of agreements underway, Avrio has continued to value the core principles of its affiliate, Irvine Pharmaceutical Services.  "For the past 22 years we have been dedicated to continual improvement of our systems and infrastructures in order to better serve the needs of our clients," said Assad J. Kazeminy, CEO and Founder of Irvine Pharmaceutical Services. "With the addition of Avrio, we can now support our clients from start to finish via a seamless partnership."

You can learn more about Avrio and the executive team at the upcoming 2010 PDA Annual Meeting, booth 714.

About Avrio Biopharmaceuticals, LLC

Avrio Biopharma, an affiliate of Irvine Pharmaceutical Services, is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Avrio, along with its Irvine affiliate, offers full cGMP product development support, specializing in preformulation/formulation, analytical development, process validation, scale-up studies, packaging and labeling, stability storage and complete analytical CMC testing. Learn more at www.avriobiopharma.com or call 866-98-AVRIO (866-982-8746).

SOURCE Avrio Biopharmaceuticals, LLC

RELATED LINKS
http://www.avriobiopharma.com
http://www.irvinepharma.com

'/>"/>

SOURCE Avrio Biopharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter
2. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
3. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
4. Lillys Online, Interactive Health Education Program Receives Two Web Awards
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. INNOPHARMA Receives First FDA Approval
7. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
8. Mylan Receives Approval for Generic Version of GoLytely(R)
9. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
10. Notal Visions ForeseeHome(TM) AMD Monitor Receives FDA Clearance
11. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for the total ... and sex in these markets. GD epidemiology report is written and developed ... transparent and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... 4, 2016  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, announced today that ... agreement with Morgan Stanley & Co. LLC to repurchase ... part of the Company,s previously authorized program to repurchase ... --> --> ...
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... in the United States District Court for the District of ... (the "Class") consisting of all persons or entities who purchased ... (NASDAQ: INSY ) from March 3, 2015 through January ... certain of its officers with violations of the Securities Exchange ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon and ... cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery ... three-year term as chief and began a second three-year term in January of 2016. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Atlanta, Georgia (PRWEB) , ... February 05, 2016 , ... ... pleased to announce their 2nd Annual No Cost Dental Day to individuals in need. ... 4pm. The purpose of this No Cost Dental Day is to provide dental care ...
(Date:2/5/2016)... ... , ... Health and wellness is a topic that should concern all Americans; ... experiencing an illness. Migraines are a severe form of a headache and often are ... wish the pain on their worst enemy, the feeling can last for many hours ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... –This ... on the benefits of having a tankless water heater. To view the report, ... water heaters: tank and tankless. While each has their pros and cons, the type ...
Breaking Medicine News(10 mins):